Novartis Pharma and Xenon entered into research & development agreement for Xenon’s preclinical stearoyl-CoA desaturase-1 (SCD-1) drug development program for treating obesity and other metabolic diseases including metabolic syndrome. The deal could be worth up to US$157 M to Xenon.